



# ASX Release

EMVision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## EMVISION AND METRO SOUTH HEALTH SIGN CLINICAL RESEARCH AND INNOVATION PARTNERSHIP

### Highlights:

- *EMVision and Metro South Health execute research and innovation partnership to continue to advance and translate EMVision's novel electromagnetic imaging into products that improve patient outcomes.*
- *Key elements of the partnership are collaborative research and innovation activities focused on areas that combine EMVision's novel brain scanner technology and Metro South Health's clinical expertise, including preparation for EMVision's planned expanded clinical studies.*
- *Under the agreement Metro South Health will provide EMVision with access to neurology, radiology and critical care expertise, assistance with expanded clinical study design and development, access to simulation rooms and hospital infrastructure, advancement of bedside processes as well as input into technology development.*
- *This partnership places EMVision in a unique relationship with a major health network that provides specialist health care to a population of more than 1 million people.*

**EMvision Medical Devices Limited (ASX:EMV)** ("EMVision" or the "Company"), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to advise that it has signed a clinical expertise, research and innovation collaboration with Metro South Health ("MSH").

The objective of this collaboration is to leverage the input of a network of clinical experts to advance and translate EMVision's novel electromagnetic imaging into commercially successful products that improve patient outcomes. MSH is the major provider of public health care in Brisbane south side, Logan, Redlands and Scenic Rim regions. It runs five hospitals, including the Princess Alexandra Hospital, Brisbane, Logan Hospital, Queen Elizabeth II Jubilee Hospital, Beaudesert Hospital and a network of community health centres. The majority of research activities, across neurology, radiology and intensive care units (ICU) are expected to be carried out at the Princess Alexandra Hospital, Brisbane, which has been the site for EMVision's pilot clinical study. The Princess Alexandra Hospital will have access to EMVision's latest technology.

Key parts of the collaboration include expert clinical advice, input, analysis, review and contributions to the design and development of devices, the bedside and pre-hospital workflows, the simulation of patient bedside care, the specifications, evaluation and use of the device as well as end user acceptance testing. Any new intellectual property created during the collaboration will vest with EMVision. This agreement is separate to any clinical trial contracts. The term of the collaboration is one year unless it is renewed and EMVision will contribute \$215,500 in research funding over the term.

Chair of Metro South Research, Professor John Upham, said “the health service is committed to research and innovation that is at the forefront of patient care. Metro South Health is a leader in providing cutting edge treatments across the clinical spectrum and actively engages in clinical trials that advance best practice care for patients now and into the future.”

EMVision CEO, Dr Ron Weinberger, commented “Metro South Health, is one of the leading regional healthcare groups in Australia with state-of-the-art facilities and clinical expertise. Collaboration of this kind for emerging medical device companies is a best practice model in countries with world leading health technology advances but is less prevalent in Australia. Metro South Health is following this best practice path while allowing EMVision exceptional access to a very large pool of clinical expertise that is unusual for a company of our size. Our partnership with Princess Alexandra Hospital has been exceptional and EMVision is very fortunate to now grow our collaboration with Metro South Health.”

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Investor Relations  
+61 400 400 800  
andrew.keys@keysthomas.com

Sling & Stone  
Media and Communications  
emvision@slingstone.com  
02 8073 5390

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## **About EMVision Medical Devices**

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.6 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on

these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.